Horizon Medical Products Will Relieve Debt Load With IPO Proceeds
This article was originally published in The Gray Sheet
Executive Summary
Horizon Medical Products is earmarking the lion's share of $31.6 mil. in anticipated net proceeds from a planned initial public offering to settle outstanding debt related to the firm's July 15 acquisition of Pfizer's Strato/Infusaid business and its October 1995 purchase of NeoStar Medical Technologies.